Risk of cardiovascular events associated with selective COX-2 inhibitors

Journal of the American Medical Association

Volumn 286, Issue 8, 2001, Pages 954-959

  Mukherjee, D ^a   Nissen, S E ^a   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DATA BASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART INFARCTION; HUMAN; INTRACARDIAC THROMBOSIS; META ANALYSIS; PRIORITY JOURNAL; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 0035934070     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.8.954     Document Type: Article

References (39)

1. Anti-inflammatory drugs and their mechanism of action
2. The induction and suppression of prostaglandin H2 synthase (cydooxygenase) in human monocytes
3. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
4. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells
5. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis
6. Inflammation and coronary heart disease: An overview
7. The cyclooxy-genase-2 inhibitors: Safety and effectiveness
8. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor tofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
9. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteo-arthritis
10. Outcome of specific COX-2 inhibition in rheumatoid arthritis
11. Celecoxib for rheumatoid arthritis
12. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
13. COX-2 inhibitors and renal function in elderly people
14. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteo-arthritis
15. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
16. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
18. Gastro-intestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatold arthritis: The CLASS study: A randomized controlled trial
19. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
20. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
21. Effects of specific inhibition of cyctooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
22. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
23. Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: Results of a combined analysis
24. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: A retrospective cohort study from disease onset
25. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
26. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 vetsus COX-1 in healthy volunteers
27. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious tabbits
28. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomized controlled trial
29. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence
30. Blood pressure, stroke, and coronary heart disease, II: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
31. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
32. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies
33. Inflammation and thrombosis: The clot thickens
34. Coronary artery disease: An inflammatory or infectious process